Xu jianmin
10
0
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
40%
4 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Robotic Versus Laparoscopic Surgery for Middle and Low Rectal Cancer: a Target Trial Emulation
Role: lead
Laparoscopic Versus Open Right Hemicolectomy Within ERAS in Right-sided Colon Cancer
Role: lead
Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Role: lead
A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer
Role: lead
Minimally Invasive Versus Open Liver Resection for Patients With Colorectal Cancer Liver Metastases
Role: lead
Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases
Role: lead
A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer
Role: lead
Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
Role: lead
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
Role: lead
Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases
Role: lead
All 10 trials loaded